RESUMEN
OBJECTIVE: Similar to pregnant women, women taking an oral contraceptive (OC) might have elevated iodine requirements due to the altered hormonal state. This is the first study aimed at investigating the prevalence of iodine deficiency and possible influences of OC intake on urine creatinine and iodine levels in young women. METHODS: One hundred fifty-five women between the age of 18 and 35 years (62 taking an OC and 93 controls) participated in a cross-sectional pilot study at the Medical University of Vienna, which included a 1-spot urine sample and a questionnaire on OC intake as well as a food questionnaire. RESULTS: The median urinary iodine concentration (UIC) in this study was 68 µg/L (41, 111 µg/L) suggesting an inadequate iodine status in the women according to the WHO guidelines. Median UIC (OC: 89 µg/L, IQR 55-120; control: 59 µg/L, IQR 39-91, p = 0.010) and urine creatinine (OC: median = 99.0 µg/L, IQR 74.9-175.5; control: 77.0 µg/L, IQR 49.6-147.2, p = 0.030) levels were significantly higher in OC women than in the control group. UIC corrected for urine creatinine was comparable between both groups. CONCLUSION: With similar creatinine-corrected UICs in both groups, OC intake might not have a significant impact on iodine status. However, the low median UIC in a vulnerable group of young women potentially conceiving in the following years points at the necessity of optimizing the iodine intake in the Austrian population and reiterates the insufficiency of the current iodine supplementation measures.
Asunto(s)
Anticonceptivos Orales/efectos adversos , Yodo/deficiencia , Yodo/orina , Adolescente , Austria/epidemiología , Anticonceptivos Orales/administración & dosificación , Creatinina/orina , Estudios Transversales , Enfermedades Carenciales/epidemiología , Enfermedades Carenciales/orina , Femenino , Humanos , Estado Nutricional , Proyectos Piloto , Embarazo , Prevalencia , Adulto JovenRESUMEN
Oral contraceptive use has been associated with decreased menstrual blood losses; thus, can independently reduce the risk of anemia and iron deficiency in women. Manufacturers have recently started to include supplemental iron in the non-hormonal placebo tablets of some contraceptives. The aims of this narrative review are: (i) to describe the relationship between oral contraceptive use and both anemia and iron status in women; (ii) to describe the current formulations of iron-containing oral contraceptives (ICOC) available on the market; and (iii) to systematically review the existing literature on the effect of ICOC on biomarkers of anemia and iron status in women. We discovered 21 brands of ICOC, most commonly including 25 mg elemental iron as ferrous fumarate, for seven days, per monthly tablet package. Our search identified one randomized trial evaluating the effectiveness of ICOC use compared to two non-ICOC on increasing hemoglobin (Hb) and iron status biomarker concentrations in women; whereafter 12 months of contraception use, there were no significant differences in Hb concentration nor markers of iron status between the groups. ICOC has the potential to be a cost-effective solution to address both family planning needs and iron deficiency anemia. Yet, more rigorous trials evaluating the effectiveness of ICOC on improving markers of anemia and iron deficiency, as well as investigating the safety of its consumption among iron-replete populations, are warranted.
Asunto(s)
Anticonceptivos Orales/química , Compuestos Ferrosos/sangre , Hemoglobinas/efectos de los fármacos , Hierro/administración & dosificación , Adulto , Anemia Ferropénica/sangre , Anemia Ferropénica/tratamiento farmacológico , Biomarcadores/sangre , Anticonceptivos Orales/administración & dosificación , Servicios de Planificación Familiar/métodos , Femenino , Humanos , Hierro/análisisRESUMEN
The public health relevance of drug-nutrition interactions is currently highly undervalued and overlooked. This is particularly the case for elderly persons where multi-morbidity and consequently polypharmacy is very common. Vitamins and other micronutrients have central functions in metabolism, and their interactions with drugs may result in clinically relevant physiological impairments but possibly also in positive effects. On 12 April 2016, the University Medical Center Groningen (The Netherlands), as part of its Healthy Ageing program, organized a workshop on the public health relevance of drug-nutrient interactions. In this meeting, experts in the field presented results from recent studies on interactions between pharmaceuticals and nutrients, and discussed the role of nutrition for elderly, focusing on those persons receiving pharmaceutical treatment. This paper summarizes the proceedings of the symposium and provides an outlook for future research needs and public health measures. Since food, pharma and health are closely interconnected domains, awareness is needed in the medical community about the potential relevance of drug-nutrition interactions. Experts and stakeholders should advocate for the integration of drug-nutrition evaluations in the drug development process. Strategies for the individual patients should be developed, by installing drug review protocols, screening for malnutrition and integrating this topic into the general medical advice.
Asunto(s)
Interacciones Alimento-Droga , Salud Pública , Anticonceptivos Orales/administración & dosificación , Anticonceptivos Orales/sangre , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/diagnóstico , Ácidos Grasos Omega-3/administración & dosificación , Ácidos Grasos Omega-3/sangre , Femenino , Ácido Fólico/administración & dosificación , Ácido Fólico/sangre , Microbioma Gastrointestinal/efectos de los fármacos , Humanos , Masculino , Metaanálisis como Asunto , Micronutrientes/administración & dosificación , Micronutrientes/sangre , Países Bajos , Estado Nutricional , Vitamina D/administración & dosificación , Vitamina D/sangre , Vitamina K/administración & dosificación , Vitamina K/sangreRESUMEN
BACKGROUND: Oral contraceptives (OC) are associated with a decreased risk of colorectal cancers; however, a recent study reported an increased risk of small colorectal adenomas associated with OC use. To determine if these results were replicable in a different study population, we investigated the relationship between OC use and other reproductive factors and risk of colorectal polyps in a case-control study in western Washington. METHODS: Study participants were 24-79-year-old female enrollees at an integrated health care system in western Washington who were diagnosed as having adenomas (n = 299), serrated polyps (n = 337), both types of polyps (n = 105) or as polyp-free controls (n = 615) through an index colonoscopy and completed a structured interview to collect reproductive history information. Multivariable polytomous logistic regression was used to compare case groups to controls and to each other; odds ratios (OR) and 95% confidence intervals were estimated. RESULTS: There was no association between OC use, duration of use, or recency of use and the risk of either adenomas or serrated polyps [adjusted OR for OC ever use (95% CI) 0.85 (0.58-1.23) and 0.96 (0.66-1.40), respectively], and associations did not differ by lesion severity within the adenoma or serrated pathways. Further, no associations were observed between other reproductive factors and risk of colorectal polyp subtypes. CONCLUSIONS: Our results suggest that reproductive factors, including OC use, are not associated with early colorectal cancer precursor lesions.
Asunto(s)
Pólipos del Colon/epidemiología , Anticonceptivos Orales , Historia Reproductiva , Adenoma/epidemiología , Adulto , Anciano , Estudios de Casos y Controles , Pólipos del Colon/diagnóstico , Colonoscopía , Neoplasias Colorrectales/epidemiología , Anticonceptivos Orales/administración & dosificación , Femenino , Humanos , Modelos Logísticos , Persona de Mediana Edad , Oportunidad Relativa , Factores de Riesgo , WashingtónRESUMEN
CONTEXT: The literature presents contradictory results regarding the effects of contraceptives on cardiac autonomic regulation. OBJECTIVE: The research team aimed to evaluate the effects of musical auditory stimulation on cardiac autonomic regulation in women who use oral contraceptives. DESIGN: The research team designed a transversal observational pilot study. SETTING: The setting was the Centro de Estudos do Sistema Nervoso Autônomo (CESNA) in the Departamento de Fonoaudiologia at the Universidade Estadual Paulista (UNESP) in Marília, SP, Brazil. PARTICIPANTS: Participants were 22 healthy nonathletic and nonsedentary females, all nonsmokers and aged between 18 and 27 y. INTERVENTIONS: Participants were divided into 2 groups: (1) 12 women who were not taking oral contraceptives, the control group; and (2) 10 women who were taking oral contraceptives, the oral contraceptive group. In the first stage, a rest control, the women sat with their earphones turned off for 20 min. After that period, the participants were exposed to 20 min of classical baroque music (ie, "Canon in D Major," Johann Pachelbel), at 63-84 dB. OUTCOME MEASURES: Measurements of the equivalent sound levels were conducted in a soundproof room, and the intervals between consecutive heartbeats (R-R intervals) were recorded, with a sampling rate of 1000 Hz. For calculation of the linear indices, the research team used software to perform an analysis of heart rate variability (HRV). Linear indices of HRV were analyzed in the time domain: (1) the standard deviation of normal-to-normal R-R intervals (SDNN), (2) the root-mean square of differences between adjacent normal R-R intervals in a time interval (RMSSD), and (3) the percentage of adjacent R-R intervals with a difference of duration greater than 50 ms (pNN50). The study also analyzed the frequency domain-low frequency (LF), high frequency (HF), and LF/HF ratio. RESULTS: For the control group, the musical auditory stimulation reduced (1) the SDNN from 52.2 ± 10 ms to 48.4 ± 16 ms (P = .0034); (2) the RMSSD from 45.8 ± 22 ms to 41.2 ± 19 ms (P = .0128); (3) the pNN50 from 25.5 ± 19 to 22.0 ± 18 (P = .0211); and (4) the LF (ms2) from 954.8 ± 457 ms2 to 686.2 ± 491 ms2 (P = .0024). In the oral contraceptive group, no significant changes occurred for the HRV indices during exposure to music. CONCLUSIONS: Musical auditory stimulation had a greater influence on cardiac autonomic regulation in women who did not use oral contraceptives.
Asunto(s)
Estimulación Acústica/métodos , Sistema Nervioso Autónomo/fisiología , Anticonceptivos Orales/administración & dosificación , Frecuencia Cardíaca/fisiología , Música , Adulto , Sistema Nervioso Autónomo/efectos de los fármacos , Brasil , Femenino , Humanos , Proyectos Piloto , Valores de Referencia , Estadísticas no Paramétricas , Adulto JovenRESUMEN
BACKGROUND: Low chronic vitamin B-6 status can occur in a subset of women who use oral contraceptives (OCs) with uncertain metabolic consequences. An insufficiency of cellular pyridoxal 5'-phosphate (PLP), which is the coenzyme form of vitamin B-6, may impair many metabolic processes including one-carbon and tryptophan metabolism. OBJECTIVE: We investigated the effects of vitamin B-6 supplementation on the in vivo kinetics of one-carbon metabolism and the concentration of one-carbon and tryptophan metabolites in vitamin B-6-deficient OC users. DESIGN: A primed, constant infusion of [(13)C5]methionine, [3-(13)C]serine, and [(2)H3]leucine was performed on 10 OC users (20-40 y old; plasma PLP concentrations <30 nmol/L) before and after 28 d of supplementation with 10 mg pyridoxine hydrochloric acid/d. In vivo fluxes of total homocysteine remethylation, the remethylation of homocysteine from serine, and rates of homocysteine and cystathionine production were assessed. Targeted metabolite profiling was performed, and data were analyzed by using orthogonal partial least-squares-discriminant analysis and paired t tests adjusted for multiple testing. RESULTS: Pyridoxine supplementation increased the mean ± SD plasma PLP concentration from 25.8 ± 3.6 to 143 ± 58 nmol/L (P < 0.001) and decreased the leucine concentration from 103 ± 17 to 90 ± 20 nmol/L (P = 0.007) and glycine concentration from 317 ± 63 to 267 ± 58 nmol/L (P = 0.03). Supplementation did not affect in vivo rates of homocysteine remethylation or the appearance of homocysteine and cystathionine. A multivariate analysis showed a clear overall effect on metabolite profiles resulting from supplementation. Leucine, glycine, choline, cysteine, glutathione, trimethylamine N-oxide, and the ratios glycine:serine, 3-hydroxykynurenine:kynurenine, 3-hydroxykynurenine:3-hydroxyanthranilic acid, and 3-hydroxykynurenine:anthranilic acid were significant discriminating variables. CONCLUSIONS: Consistent with previous vitamin B-6-restriction studies, fluxes of one-carbon metabolic processes exhibited little or no change after supplementation in low-vitamin B-6 subjects. In contrast, changes in the metabolic profiles after supplementation indicated perturbations in metabolism, suggesting functional vitamin B-6 deficiency. This study was registered at clinicaltrials.gov as NCT01128244.
Asunto(s)
Anticonceptivos Orales/efectos adversos , Piridoxina/administración & dosificación , Piridoxina/sangre , Triptófano/sangre , Deficiencia de Vitamina B 6/sangre , Ácido 3-Hidroxiantranílico/metabolismo , Adulto , Biomarcadores/sangre , Carbono/metabolismo , Anticonceptivos Orales/administración & dosificación , Cistationina/sangre , Suplementos Dietéticos , Femenino , Glicina/sangre , Homocisteína/sangre , Humanos , Quinurenina/análogos & derivados , Quinurenina/sangre , Leucina/sangre , Metionina/sangre , Metilaminas/sangre , Análisis Multivariante , Fosfato de Piridoxal/sangre , Serina/sangre , Deficiencia de Vitamina B 6/etiología , Adulto JovenRESUMEN
Ethinyl Estradiol (EE), a synthetic, orally bio-available estrogen, is the most commonly prescribed form of estrogen in oral contraceptives, and is found in at least 30 different contraceptive formulations currently prescribed to women as well as hormone therapies prescribed to menopausal women. Thus, EE is prescribed clinically to women at ages ranging from puberty to reproductive senescence. Here, in two separate studies, the cognitive effects of cyclic or tonic EE administration following ovariectomy (Ovx) were evaluated in young female rats. Study I assessed the cognitive effects of low and high doses of EE, delivered tonically via a subcutaneous osmotic pump. Study II evaluated the cognitive effects of low, medium, and high doses of EE administered via a daily subcutaneous injection, modeling the daily rise and fall of serum EE levels with oral regimens. Study II also investigated the impact of low, medium and high doses of EE on the basal forebrain cholinergic system. The low and medium doses utilized here correspond to the range of doses currently used in clinical formulations, and the high dose corresponds to doses prescribed to a generation of women between 1960 and 1970, when oral contraceptives first became available. We evaluate cognition using a battery of maze tasks tapping several domains of spatial learning and memory as well as basal forebrain cholinergic integrity using immunohistochemistry and unbiased stereology to estimate the number of choline acetyltransferase (ChAT)-producing cells in the medial septum and vertical/diagonal bands. At the highest dose, EE treatment impaired multiple domains of spatial memory relative to vehicle treatment, regardless of administration method. When given cyclically at the low and medium doses, EE did not impact working memory, but transiently impaired reference memory during the learning phase of testing. Of the doses and regimens tested here, only EE at the highest dose impaired several domains of memory; tonic delivery of low EE, a dose that corresponds to the most popular doses used in the clinic today, did not impact cognition on any measure. Both medium and high injection doses of EE reduced the number of ChAt-immunoreactive cells in the basal forebrain, and cell population estimates in the vertical/diagonal bands negatively correlated with working memory errors.
Asunto(s)
Prosencéfalo Basal/efectos de los fármacos , Neuronas Colinérgicas/efectos de los fármacos , Cognición/efectos de los fármacos , Etinilestradiol/toxicidad , Trastornos de la Memoria/inducido químicamente , Animales , Anticonceptivos Orales/administración & dosificación , Anticonceptivos Orales/toxicidad , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Etinilestradiol/administración & dosificación , Femenino , Aprendizaje por Laberinto/efectos de los fármacos , Memoria/efectos de los fármacos , Distribución Aleatoria , Ratas , Ratas Endogámicas F344RESUMEN
INTRODUCTION: Vulvovaginal candidiasis is the most common mycosis, however, the available information about antifungal susceptibilities of these yeasts is limited. AIM: To compare the gold standard fungal culture with a new molecular identification method and report the incidence of yeast species in vulvovaginitis candidosa. METHOD: The authors studied 370 yeasts isolated from vulvovaginal candidiasis and identified them by phenotypic and molecular methods. RESULTS: The most common species was Candida albicans (85%), followed by Candida glabrata, and other Candida species. CONCLUSION: At present there are no recommendations for the evaluation of antifungal susceptibility of pathogenic fungal species occurring in vulvovaginal candidiasis and the natural antifungal resistance of the different species is known only. Matrix Assisted Laser Desorption Ionization Time of Flight identification can be used to differentiate the fluconazole resistant Candida dubliniensis and the sensitive Candida albicans strains.
Asunto(s)
Antifúngicos/uso terapéutico , Candida/aislamiento & purificación , Candidiasis Vulvovaginal/diagnóstico , Candidiasis Vulvovaginal/tratamiento farmacológico , Administración Intravaginal , Administración Oral , Adulto , Anciano , Antibacterianos/administración & dosificación , Antibacterianos/efectos adversos , Antifúngicos/administración & dosificación , Candida albicans/aislamiento & purificación , Candida glabrata/aislamiento & purificación , Candida tropicalis/aislamiento & purificación , Anticonceptivos Orales/administración & dosificación , Anticonceptivos Orales/efectos adversos , Complicaciones de la Diabetes/microbiología , Femenino , Fluconazol/uso terapéutico , Humanos , Hungría , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Estudios Retrospectivos , Factores de RiesgoRESUMEN
Previous studies of oral contraceptives and breast cancer indicate that recent use slightly increases risk, but most studies relied on self-reported use and did not examine contemporary oral contraceptive formulations. This nested case-control study was among female enrollees in a large U.S. integrated health care delivery system. Cases were 1,102 women ages 20 to 49 years diagnosed with invasive breast cancer from 1990 to 2009. Controls were randomly sampled from enrollment records (n = 21,952) and matched to cases on age, year, enrollment length, and medical chart availability. Detailed oral contraceptive use information was ascertained from electronic pharmacy records and analyzed using conditional logistic regression, ORs, and 95% confidence intervals (CI). Recent oral contraceptive use (within the prior year) was associated with an increased breast cancer risk (OR, 1.5; 95% CI, 1.3-1.9) relative to never or former OC use. The association was stronger for estrogen receptor-positive (ER(+); OR, 1.7; 95% CI, 1.3-2.1) than estrogen receptor-negative (ER(-)) disease (OR, 1.2, 95% CI, 0.8-1.8), although not statistically significantly different (P = 0.15). Recent use of oral contraceptives involving high-dose estrogen (OR, 2.7; 95% CI, 1.1-6.2), ethynodiol diacetate (OR, 2.6; 95% CI, 1.4-4.7), or triphasic dosing with an average of 0.75 mg of norethindrone (OR, 3.1; 95% CI, 1.9-5.1; Pheterogeneity compared with using other oral contraceptives = 0.004) was associated with particularly elevated risks, whereas other types, including low-dose estrogen oral contraceptives, were not (OR, 1.0; 95% CI, 0.6-1.7). Our results suggest that recent use of contemporary oral contraceptives is associated with an increased breast cancer risk, which may vary by formulation. If confirmed, consideration of the breast cancer risk associated with different oral contraceptive types could impact discussions weighing recognized health benefits and potential risks.
Asunto(s)
Neoplasias de la Mama/epidemiología , Anticonceptivos Orales/administración & dosificación , Anticonceptivos Orales/química , Adulto , Neoplasias de la Mama/inducido químicamente , Estudios de Casos y Controles , Anticonceptivos Orales/efectos adversos , Femenino , Humanos , Persona de Mediana Edad , Factores de Riesgo , Estados Unidos/epidemiología , Adulto JovenRESUMEN
BACKGROUND: Endometriosis affects fertility negatively. The study aims to evaluate whether laparoscopic surgery combined with oral contraceptive or herbs were more effective than laparoscopic alone in improving fecundity and pelvic pain in women with minimal/mild endometriosis. METHODS: A randomized controlled trial (RCT) was conducted in 156 infertile women with minimal/mild endometriosis. After laparoscopic surgery, patients were randomized to three groups: in Group A (n = 52) oral contraceptive (OC) was administered one pill a day, continuous for 63 days without intervals, in Group B (n = 52) OC was administered as above and then Dan'e mixture was added 30 g/day for the latter 30 days, and in control Group C (n = 52) patients tried to get pregnant after surgery without complementary treatment. The follow-up periods were 12 months in Group C and 14 months in complementary medical treatment Group A and B. The pregnant women were further followed up, and labor and pregnancy outcomes were assessed. Primary outcome was pregnancy rate (PR) and live birth rate (LBR). Secondary outcomes included changes of pelvic pain visual analog scale scores and side effects. Analyses were done as intention-to-treat. RESULTS: The PR was 46.80% (73/156), and the LBR was 69.86% (51/73). Of the 73 pregnancies, 60 occurred within 12 months of follow-up and 7 of the remaining 13 patients underwent assisted reproductive technology for >1 year. No significant difference was observed in PR and LBR among the three groups. Patients given medical treatment (OCs or OCs plus herbal medicine) had significantly decreased pain scores compared with the laparoscopy alone group. CONCLUSIONS: Combination of laparoscopy with OCs or OCs and herbal medicine does not have more advantages than laparoscopy alone in improving fertility of women with minimal/mild endometriosis. TRIAL REGISTRATION: ChiCTR-TRC-11001820.
Asunto(s)
Anticonceptivos Orales/administración & dosificación , Medicamentos Herbarios Chinos/administración & dosificación , Endometriosis/tratamiento farmacológico , Infertilidad Femenina/tratamiento farmacológico , Dolor Pélvico/tratamiento farmacológico , Adulto , Terapia Combinada , Anticonceptivos Orales/efectos adversos , Medicamentos Herbarios Chinos/efectos adversos , Endometriosis/complicaciones , Endometriosis/cirugía , Femenino , Fertilidad , Humanos , Infertilidad Femenina/etiología , Infertilidad Femenina/cirugía , Laparoscopía , Dolor Pélvico/etiología , Dolor Pélvico/cirugía , Embarazo , Resultado del Embarazo , Estudios Prospectivos , Adulto JovenRESUMEN
BACKGROUND: National sexual health frameworks in the UK advise that women in maternity units who are at risk of unintended pregnancy should receive contraceptive advice and supplies of the most effective long-acting reversible methods of contraception (LARC). In the UK, midwives currently deliver contraceptive advice to women following childbirth. There is a lack of information on how midwives currently view their role as provider of contraceptive advice and how they would feel about expanding this to include provision of LARC. OBJECTIVE: To explore midwives' experiences and views of giving postpartum contraceptive advice and of possible expansion of role to include provision of LARC. METHODS: Semi-structured, audio-recorded interviews were carried out with 12 midwives involved in the postpartum care of women in Edinburgh, Scotland, UK. Interviews were transcribed verbatim and analysed using thematic analysis. RESULTS: Midwives confirmed that they all routinely give contraceptive advice but that this was mostly cursory. They viewed this part of their job as of lesser importance and one that they felt inadequately trained for. Many barriers to discussing contraception were identified including lack of time and privacy, or mothers being preoccupied with concerns about their baby. Midwives expressed concern about taking on a greater role in giving contraceptive advice or providing LARC, given their current heavy workload. CONCLUSIONS: Midwives require ongoing training and support to be effective in their current role as provider of contraceptive advice. Better links between midwifery and specialist sexual and reproductive health services should therefore be encouraged, particularly if a midwife's role is expanded to include provision of contraception such as LARC.
Asunto(s)
Actitud del Personal de Salud , Anticoncepción/métodos , Anticonceptivos Orales/administración & dosificación , Educación del Paciente como Asunto/métodos , Adolescente , Adulto , Estudios Transversales , Femenino , Humanos , Entrevistas como Asunto , Partería/métodos , Enfermeras Obstetrices , Periodo Posparto , Embarazo , Embarazo no Planeado , Investigación Cualitativa , Escocia , Adulto JovenRESUMEN
Vitamins B(6), B(12) and folate play crucial metabolic roles especially during the reproductive years for women. There is limited reporting of within-subject variability of these vitamins. This study aimed to determine the within and between subject variability in serum vitamins B(6), B(12), folate and erythrocyte folate concentrations in young women; identify factors that contribute to variability; and determine dietary intakes and sources of these vitamins. Data were obtained from the control group of a trial aimed at investigating the effect of iron on the nutritional status of young women (age 25.2 ± 4.2 year; BMI 21.9 ± 2.2 kg/m2). The coefficients of variability within-subject (CVI) and between-subject (CVG) for serum vitamins B(6), B(12)and folate, and erythrocyte folate were calculated. Food frequency questionnaires provided dietary data. CVI and CVG were in the range 16.1%-25.7% and 31.7%-62.2%, respectively. Oral contraceptive pill (OCP) use was associated (P = 0.042) with lower serum vitamin B12 concentrations. Initial values were 172 ± 16 pmol/L and 318 ± 51 pmol/L for OCP and non-OCP users, respectively; with differences maintained at four time points over 12 weeks. BMI, age, physical activity, alcohol intake and haematological variables did not affect serum or erythrocyte vitamin concentrations. Vitamin B12 intakes were derived from traditional and unexpected sources including commercial energy drinks. Young women using OCP had significantly lower serum vitamin B12 concentrations. This should be considered in clinical decision making and requires further investigation.
Asunto(s)
Anticonceptivos Orales/administración & dosificación , Ácido Fólico/sangre , Estado Nutricional , Vitamina B 12/sangre , Vitamina B 6/sangre , Adolescente , Adulto , Disponibilidad Biológica , Suplementos Dietéticos , Ingestión de Energía , Ejercicio Físico , Femenino , Ácido Fólico/administración & dosificación , Ácido Fólico/farmacocinética , Humanos , Estilo de Vida , Estudios Longitudinales , Análisis de Regresión , Encuestas y Cuestionarios , Vitamina B 12/administración & dosificación , Vitamina B 12/farmacocinética , Vitamina B 6/administración & dosificación , Vitamina B 6/farmacocinética , Adulto JovenRESUMEN
PURPOSE: To evaluate if the degree of recovery of serum gonadotropins after oral contraceptive pills (OCP) pretreatment has an impact on ovarian response in GnRH-antagonist IVF cycles in women of advanced maternal age. METHODS: In this retrospective cohort study, we included 98 women 35-42 years undergoing their first IVF cycle receiving gonadotropins and a fixed GnRH-antagonist adjuvant protocol. Data analysis was carried out according to changes in serum FSH, LH and estradiol (E(2)) levels (basal and post-OCP) divided in quartiles, and also according to absolute levels. The main outcomes were peak serum E(2), number of mature oocytes retrieved, length of stimulation, and amount of gonadotropins used. RESULTS: By quartile analysis, patients with the highest levels of serum gonadotropins suppression and also patients with gonadotropin rebound needed larger amounts of LH during the treatment. On the other hand, women with absolute suppression of FSH/LH had increased length of stimulation. CONCLUSIONS: The results of this study provide data that assist in clinical management. Gonadotropin serum levels after OCP treatment provide information for optimization of supplementation with LH in GnRH-antagonist cycles in women over age 35.
Asunto(s)
Anticonceptivos Orales/farmacología , Fertilización In Vitro/métodos , Hormona Liberadora de Gonadotropina/antagonistas & inhibidores , Hipotálamo/efectos de los fármacos , Hipófisis/efectos de los fármacos , Inyecciones de Esperma Intracitoplasmáticas/métodos , Adulto , Anticonceptivos Orales/administración & dosificación , Transferencia de Embrión/métodos , Estradiol/sangre , Femenino , Hormona Folículo Estimulante/administración & dosificación , Hormona Folículo Estimulante/sangre , Hormona Folículo Estimulante/farmacología , Humanos , Infertilidad Femenina/tratamiento farmacológico , Hormona Luteinizante/sangre , Recuperación del Oocito/métodos , Ovario/efectos de los fármacos , Inducción de la Ovulación/métodos , Embarazo , Resultado del Embarazo , Estudios Retrospectivos , Estadísticas no Paramétricas , Factores de Tiempo , Resultado del TratamientoRESUMEN
BACKGROUND/AIMS: To review the main results of intervention trials which showed the efficacy of periconceptional folic acid-containing multivitamin and folic acid supplementation in the prevention of neural-tube defects (NTD). METHODS AND RESULTS: The main findings of 5 intervention trials are known: (i) the efficacy of a multivitamin containing 0.36 mg folic acid in a UK nonrandomized controlled trial resulted in an 83-91% reduction in NTD recurrence, while the results of the Hungarian (ii) randomized controlled trial and (iii) cohort-controlled trial using a multivitamin containing 0.8 mg folic acid showed 93 and 89% reductions in the first occurrence of NTD, respectively. On the other hand, (iv) another multicenter randomized controlled trial proved a 71% efficacy of 4 mg folic acid in the reduction of recurrent NTD, while (v) a public health-oriented Chinese-US trial showed a 41-79% reduction in the first occurrence of NTD depending on the incidence of NTD. CONCLUSIONS: Translational application of these findings could result in a breakthrough in the primary prevention of NTD, but so far this is not widely applied in practice. The benefits and drawbacks of 4 main possible uses of periconceptional folic acid/multivitamin supplementation, i.e. (i) dietary intake, (ii) periconceptional supplementation, (iii) flour fortification, and (iv) the recent attempt for the use of combination of oral contraceptives with 6S-5-methytetrahydrofolate (methylfolate), are discussed. Obviously, prevention of NTD is much better than the frequent elective termination of pregnancies after prenatal diagnosis of NTD fetuses.
Asunto(s)
Suplementos Dietéticos , Ácido Fólico/uso terapéutico , Fenómenos Fisiologicos Nutricionales Maternos , Defectos del Tubo Neural/prevención & control , Atención Preconceptiva , Tetrahidrofolatos/uso terapéutico , Vitaminas/administración & dosificación , Anticonceptivos Orales/administración & dosificación , Dieta/efectos adversos , Suplementos Dietéticos/análisis , Combinación de Medicamentos , Femenino , Ácido Fólico/administración & dosificación , Alimentos Fortificados/análisis , Humanos , Defectos del Tubo Neural/etiología , Prevención Secundaria , Tetrahidrofolatos/administración & dosificaciónRESUMEN
BACKGROUND: Migraine with aura (MA) is a contraindication to the use of combined oral contraceptives (COCs) because of the increased risk of ischemic stroke. Progestogen-only contraceptive pill (POP) is a safe alternative to COCs and it is preferable in women with cerebrovascular diseases or risk factors for stroke. STUDY DESIGN: Prospective diary-based pilot study. Thirty women with MA (n = 15 who have never used COCs and n = 15 who had previously used COCs were diagnosed according to the International Headache Society criteria. The observational period lasted 9 months during which women filled in a diary with the clinical characteristics of headache attacks. After a 3-month run-in period, each subject received an estrogen-free desogestrel (DSG) (75 mcg/day)-containing OC (Cerazette(®); Schering-Plough, formerly NV Organon, Oss, The Netherlands). Follow-up evaluations were planned at the end of the third and sixth month of treatment. RESULTS: The number (mean±S.D.) of migraine attacks was significantly reduced both in previous COCs users (from 3.9±1.0 to 2.9±0.8; p<.001) and nonusers (from 3.2±0.9 to 2.6±1.3; p<.02) following 6 months of POP use in comparison with the run-in period. Duration of headache pain did not differ significantly in both groups throughout the study. Interestingly enough, a beneficial POP effect on the duration (mean±S.D.) of visual aura (from 16.3±9.5 to 11.4±5.6 min) and on the total duration (mean±S.D.) of neurological symptoms (from 33.6±23.3 to 18.6±18.0 min) was only significantly reported by previous COCs users (p<.001, for both) by the end of the study period. The POP was well tolerated by each woman and the bleeding pattern was variable with a tendency towards infrequent bleeding. CONCLUSIONS: The present study supports the use of the POP containing desogestrel in a population of women with MA and underlines a positive effect on symptoms of aura, especially in MA sensitive to previous use of COCs.
Asunto(s)
Anticoncepción/métodos , Anticonceptivos Orales/administración & dosificación , Desogestrel/administración & dosificación , Migraña con Aura/fisiopatología , Progestinas/administración & dosificación , Adulto , Distribución de Chi-Cuadrado , Femenino , Humanos , Proyectos Piloto , Estudios ProspectivosRESUMEN
The enzyme-inducing antiepileptic drugs such as carbamazepine, phenytoin, barbiturates, oxcarbazepine do not allow oral contraceptives. The pregnancy must be planned. Every patient in childbearing age should be informed by her practitioner. The rule is to optimize the antiepileptic treatment before the pregnancy: less drugs, less dosages. This optimization will depend on the epileptic syndrome and the nature of the treatment. Valproate of sodium should be avoided, if possible, during pregnancy. Preconceptional supplementation by folic acid should be considered. Antiepileptic drugs monitoring is required during pregnancy. Natural delivery with peridural anaesthesiology is mandatory. The breast feeding must be considered individually.
Asunto(s)
Anticonvulsivantes/administración & dosificación , Anticonvulsivantes/efectos adversos , Anticonceptivos Orales/administración & dosificación , Anticonceptivos Orales/efectos adversos , Epilepsia/tratamiento farmacológico , Complicaciones del Embarazo/tratamiento farmacológico , Anomalías Inducidas por Medicamentos/etiología , Anomalías Inducidas por Medicamentos/prevención & control , Anestesia Epidural , Anestesia Obstétrica , Encéfalo/efectos de los fármacos , Lactancia Materna , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Monitoreo de Drogas , Quimioterapia Combinada , Electroencefalografía/efectos de los fármacos , Epilepsia/etiología , Servicios de Planificación Familiar , Femenino , Humanos , Recién Nacido , Embarazo , Complicaciones del Embarazo/etiología , Factores de Riesgo , Procesamiento de Señales Asistido por ComputadorRESUMEN
The diagnosis and management of complex and multiple inherited thrombophilias is still a challenge for the clinicians involved in this field, clinical events being the result of the interaction between genes, environmental or other acquired factors, and age. Moreover, various clinical manifestations as regards severity or type of event (venous or arterial thrombotic event, obstetrical complications) are cited in these patients. We present the case of a 20-year-old woman, with a 2-month history of third-generation contraceptive use and with recently diagnosed hypercholesterolemia, who presented ischemic events in 2 arterial territories: acute left lower limb ischemia and silent myocardial infarction. Screening tests for thrombophilia, including genetic testing, showed moderate hyperhomocysteinemia and 2 inherited thrombophilic defects. Invasive investigation of the coronary arteries showed the presence of advanced atherosclerotic disease. Management of this complex thrombophilia includes lifetime oral anticoagulation as well as a homocysteine-lowering strategy comprising lifestyle modification and group B (folic acid, B(6), B(12)) vitamin supplementing.
Asunto(s)
Anticoagulantes/administración & dosificación , Enfermedad de la Arteria Coronaria/complicaciones , Enfermedad de la Arteria Coronaria/diagnóstico , Trombofilia/complicaciones , Trombofilia/diagnóstico , Trombosis/diagnóstico , Trombosis/etiología , Complejo Vitamínico B/administración & dosificación , Adulto , Anticonceptivos Orales/administración & dosificación , Enfermedad de la Arteria Coronaria/tratamiento farmacológico , Enfermedad de la Arteria Coronaria/genética , Femenino , Humanos , Hipercolesterolemia/complicaciones , Hipercolesterolemia/diagnóstico , Hipercolesterolemia/genética , Hiperhomocisteinemia/diagnóstico , Hiperhomocisteinemia/tratamiento farmacológico , Hiperhomocisteinemia/etiología , Hiperhomocisteinemia/genética , Isquemia/diagnóstico , Isquemia/etiología , Isquemia/genética , Extremidad Inferior/irrigación sanguínea , Infarto del Miocardio/diagnóstico , Infarto del Miocardio/tratamiento farmacológico , Infarto del Miocardio/etiología , Infarto del Miocardio/genética , Trombofilia/tratamiento farmacológico , Trombofilia/genética , Trombosis/tratamiento farmacológico , Trombosis/genéticaRESUMEN
OBJECTIVE: Recent data suggest vitamin D deficiency (VDD) is associated with bacterial vaginosis (BV) during pregnancy. We hypothesized that VDD is a risk factor for BV in nonpregnant women. STUDY DESIGN: Using National Health and Nutrition Examination Survey data, we conducted multivariable logistic regression analyses stratified by pregnancy. RESULTS: VDD was associated with BV only in pregnant women (adjusted odds ratio [AOR], 2.87; 95% confidence interval [CI], 1.13-7.28). Among nonpregnant women, douching (AOR, 1.72; 95% CI, 1.25-2.37), smoking (AOR, 1.66; 95% CI, 1.23-2.24), and black race (AOR, 2.41; 95% CI, 1.67-3.47) were associated with BV; oral contraceptive use was inversely associated with BV (AOR, 0.60; 95% CI, 0.40-0.90). VDD moderated the association between smoking and BV in nonpregnant women. CONCLUSION: Risk factors for BV differ by pregnancy status. VDD was a modifiable risk factor for BV among pregnant women; evaluation of vitamin D supplementation for prevention or adjunct therapy of BV in pregnancy is warranted.
Asunto(s)
Complicaciones Infecciosas del Embarazo , Vaginosis Bacteriana/etiología , Deficiencia de Vitamina D/complicaciones , Adolescente , Adulto , Factores de Edad , Anticonceptivos Orales/administración & dosificación , Femenino , Humanos , Persona de Mediana Edad , Encuestas Nutricionales , Embarazo , Complicaciones Infecciosas del Embarazo/etnología , Complicaciones Infecciosas del Embarazo/etiología , Análisis de Regresión , Factores de Riesgo , Conducta Sexual/estadística & datos numéricos , Fumar/efectos adversos , Factores Socioeconómicos , Ducha Vaginal/efectos adversos , Vaginosis Bacteriana/etnología , Deficiencia de Vitamina D/etnología , Adulto JovenRESUMEN
The effects of progestins on the quality of bone and their influence on the risk of fractures are reviewed. Data discussed are based on experimental studies in vivo that generally lasted for longer than one year. Information is given on the background of osteoporosis and on several means of inducing changes in bone quality. In young women who start using oral contraceptives based on progestins alone shortly after pubertal development, a significant decrease in bone quality has been documented. World Health Organization experts have concluded that this is not a real argument for restrictions on the use of these contraceptives. In postmenopausal women, no evidence has been found for a bone-protective or an estrogen-antagonistic effect of progestins. A wide range of estrogens have been used that have shown positive effects on bone, which are not antagonized by progestins. The therapeutic use of high-dose megestrol acetate may result in marked negative effects on bone, leading to severe osteoporosis, possibly due to the inherent glucocorticoid activity of this progestin. Other pharmacotherapeutic agents that can be used in postmenopausal therapy, and that clearly have beneficial effects on bone, are discussed.
Asunto(s)
Huesos/efectos de los fármacos , Fracturas Óseas/prevención & control , Progestinas/administración & dosificación , Densidad Ósea/efectos de los fármacos , Regeneración Ósea/efectos de los fármacos , Ensayos Clínicos como Asunto , Anticonceptivos Orales/administración & dosificación , Femenino , Fracturas Óseas/etiología , Terapia de Reemplazo de Hormonas , Humanos , Osteoporosis/complicacionesRESUMEN
BACKGROUND: A maternal red blood cell (RBC) folate concentration > 906 nmol/L is thought to be optimal for lowering the risk of neural tube defects (NTDs) in pregnancy. Whereas the appearance of folate in RBCs has been followed during folic acid supplementation, data on elimination kinetics are not yet available. OBJECTIVE: The aim of our investigation was to estimate the steady state conditions and elimination kinetics of folate in RBCs. DESIGN: Data from 2 randomized, placebo-controlled, double-blind intervention trials were used for kinetic modeling. These studies were performed to investigate the appearance of folate in RBCs in healthy women of childbearing age after different supplementation strategies (study 1: n = 69; 400 microg folic acid/d and 416 microg [6S]-5-methyltetrahydrofolate/d for 24 wk; study 2: n = 21; 800 microg folic acid/d for 16 wk). RESULTS: For RBC folate concentrations, steady state conditions were not reached after 24 (study 1) and 16 (study 2) wk of folate supplementation. However, with the use of these data, we calculated the biological half-life (t(1/2)) of RBC folate to be approximately 8 wk. With the application of pharmacokinetic principles, steady state conditions for RBC folate should be reached after 40 wk (t(1/2) x 5). CONCLUSION: With the use of pharmacokinetic principles, the appearance and elimination kinetics of RBC folate can be calculated on the basis of this t(1/2) value.